Work

Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE

Year: 2019

Type: conference-abstract

Source: Cancer Immunology Research

DOI: 10.1158/2326-6074.cricimteatiaacr18-b207

Authors: Naiyer Rizvi, Patricia Tang, Nina Bhardwaj, Timothy A. Chan, Jeffrey S. Weber, Michael Vickers, Sofya Pintova, Holger Hirte, Neil H. Segal, Neesha Dhani, Daniel Cho, Stephen Chia, Caitlin Burns, Donsheng Tu, Laura Pearce, Alison Urton, Martin Smoragiewicz, Janet Dancey

Institutions: Memorial Sloan Kettering Cancer Center, Columbia University Irving Medical Center, Juravinski Cancer Centre, Ottawa Hospital, Princess Margaret Cancer Centre, NYU Langone Health, Tisch Cancer Institute, New York University, Icahn School of Medicine at Mount Sinai

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913180255

Cites:

Cited by: 1

Related to: 10